<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    Concord Biotech Limited: Q3 &amp; 9M FY25 Earnings Call | Financial Report Insights
    
</title>
<link href="/_pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/_pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/concord-biotech-limited-q3--9m-fy25-earnings-call2025-02-21/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/concord-biotech-limited-q3--9m-fy25-earnings-call2025-02-21/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="Concord Biotech Limited: Q3 & 9M FY25 Earnings Call">
  <meta property="og:description" content="Earnings Call Transcript Analysis Report # Financial Performance # Revenue: Q3 FY25 revenue stood at INR 244 crores compared to INR 240 crores in Q3 FY24, a 1% increase. 9 months FY25 revenue increased by 10% year-on-year to INR 770 crores (9 months FY24: INR 698 crores). EBITDA: Q3 FY25 EBITDA stood at INR 98 crores with margins at 40.1%. EBITDA for 9 months FY25 stood at INR 315 crores, representing a growth of 6% year-on-year. Profit After Tax (PAT): Q3 FY25 PAT stood at INR 76 crores with margins at 31.1%. PAT for 9 months FY25 stood at INR 231 crores as compared to INR 213 crores in the same period last year, a growth of 9% Y-o-Y. API Revenue: Q3 FY25 API revenues stood at INR 176 crores against INR 172 crores in Q3 last year, a growth of 3% year-on-year (9.6% including interunit sales). API revenue in the 9 months of this year stood at INR 577 crores against INR 562 crores during the same period last year. Formulation Revenue: Q3 FY25 Formulation segment stood at INR 67 crores. For 9 months FY25, revenues from the Formulation segment stood at INR 192 crores, up by 42% on a year-on-year basis. Guidance: Long-term guidance of achieving a 25% CAGR growth over the next 5 years is maintained. Margins: Long-term sustainable EBITDA margin guidance is in the range of 40% to 43%. Strategic Initiatives &amp; Business Updates # Product Expansion: Aim to introduce 8 to 10 additional products over the next 3 years, with a strong focus on oncology and anti-infectives. CDMO Business: Seeing a growing number of inquiries and multiple RFQs being submitted. Now seen as a medium-term growth driver. Investment in Palvella Therapeutics Inc.: Strategic investment of $1 million in compulsory convertible notes to pave the way for a strategic partnership focused on the manufacturing and commercialization of QTORIN. Investment in CleanMax Private Limited: Acquiring a 26% equity stake in CleanMax to power Dholka plant with renewable energy. Injectable Plant: Scheduled to begin commercial production in the current quarter. Sustainability: Honored with the Sustainability Reporting Award from the Institute of Chartered Accountants of India. Market &amp; Competitive Landscape # Formulation Business: Gaining strong acceptance among customers across various regions. Strategic Focus: Target domestic and emerging markets, leveraging expertise and market reach with an opportunistic approach for the regulated markets. Global Presence: Goal to establish a strong global presence and achieve market leadership, targeting a sizeable global market share within the next 5 years. Risk Factors &amp; Challenges # Customer Procurement Patterns: “Customer procurement patterns may lead to lumpiness, with some quarters experiencing higher procurement than others.” Calendar Year Closure: Formulation segment revenues were impacted due to calendar year closure for many global clients. Forward-Looking Statements # Growth Outlook: Positive outlook, in line with long-term guidance of achieving a 25% CAGR growth over the next 5 years. Formulation Business Growth: Anticipate substantial growth in both product offerings and customer acquisition in the Formulation business. CDMO Growth: CDMO is now seen as a medium-term growth driver. Injectable Plant Revenue: Revenue generation from the injectable plant is expected to build up over the next financial year. Q&amp;A Insights # Revenue Growth: Analyst questioned if the current year growth guidance would be revised downward given the trailing 12-month revenues. CDMO: Analyst questioned the CDMO contracts. Capacity Utilization: Questions regarding the capacity utilization of all facilities. Management Tone &amp; Sentiment # Stable Performance: Pleased to report stable performance for Q3 FY ‘25. Positive Outlook: Outlook remains positive, in line with long-term guidance. Emphasis on Annual Assessment: “I would still emphasize to assess our financial results on an annualized basis rather than a quarterly one.” Download Transcript">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2025-02-21T00:00:00+00:00">
    <meta property="article:modified_time" content="2025-02-21T00:00:00+00:00">
    <meta property="article:tag" content="Concord Biotech Limited">
    <meta property="article:tag" content="Earnings Call">
    <meta property="article:tag" content="February-2025">













<link rel="stylesheet" href="/assets/combined.min.83aead7461ea8e7fcfbb79b8c9400e1ec33efe08796484ba7a94d30f7b4923a8.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/concord-biotech-limited-q3--9m-fy25-earnings-call2025-02-21/">Concord Biotech Limited: Q3 &amp; 9M FY25 Earnings Call</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>Concord Biotech Limited: Q3 &amp; 9M FY25 Earnings Call</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2025-02-21T00:00:00&#43;00:00">February 21, 2025</time>
      

      
      &nbsp; · &nbsp;
      3 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/concord-biotech-limited/">#Concord Biotech Limited</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/earnings-call/">#Earnings Call</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/february-2025/">#February-2025</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#earnings-call-transcript-analysis-report">Earnings Call Transcript Analysis Report</a></li>
    <li><a href="#financial-performance">Financial Performance</a></li>
    <li><a href="#strategic-initiatives--business-updates">Strategic Initiatives &amp; Business Updates</a></li>
    <li><a href="#market--competitive-landscape">Market &amp; Competitive Landscape</a></li>
    <li><a href="#risk-factors--challenges">Risk Factors &amp; Challenges</a></li>
    <li><a href="#forward-looking-statements">Forward-Looking Statements</a></li>
    <li><a href="#qa-insights">Q&amp;A Insights</a></li>
    <li><a href="#management-tone--sentiment">Management Tone &amp; Sentiment</a></li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="earnings-call-transcript-analysis-report">
  Earnings Call Transcript Analysis Report
  <a class="anchor" href="#earnings-call-transcript-analysis-report">#</a>
</h2>
<h2 class="heading" id="financial-performance">
  Financial Performance
  <a class="anchor" href="#financial-performance">#</a>
</h2>
<ul>
<li><strong>Revenue:</strong> Q3 FY25 revenue stood at INR 244 crores compared to INR 240 crores in Q3 FY24, a 1% increase. 9 months FY25 revenue increased by 10% year-on-year to INR 770 crores (9 months FY24: INR 698 crores).</li>
<li><strong>EBITDA:</strong> Q3 FY25 EBITDA stood at INR 98 crores with margins at 40.1%. EBITDA for 9 months FY25 stood at INR 315 crores, representing a growth of 6% year-on-year.</li>
<li><strong>Profit After Tax (PAT):</strong> Q3 FY25 PAT stood at INR 76 crores with margins at 31.1%. PAT for 9 months FY25 stood at INR 231 crores as compared to INR 213 crores in the same period last year, a growth of 9% Y-o-Y.</li>
<li><strong>API Revenue:</strong> Q3 FY25 API revenues stood at INR 176 crores against INR 172 crores in Q3 last year, a growth of 3% year-on-year (9.6% including interunit sales). API revenue in the 9 months of this year stood at INR 577 crores against INR 562 crores during the same period last year.</li>
<li><strong>Formulation Revenue:</strong> Q3 FY25 Formulation segment stood at INR 67 crores. For 9 months FY25, revenues from the Formulation segment stood at INR 192 crores, up by 42% on a year-on-year basis.</li>
<li><strong>Guidance:</strong> Long-term guidance of achieving a 25% CAGR growth over the next 5 years is maintained.</li>
<li><strong>Margins:</strong> Long-term sustainable EBITDA margin guidance is in the range of 40% to 43%.</li>
</ul>
<h2 class="heading" id="strategic-initiatives--business-updates">
  Strategic Initiatives &amp; Business Updates
  <a class="anchor" href="#strategic-initiatives--business-updates">#</a>
</h2>
<ul>
<li><strong>Product Expansion:</strong> Aim to introduce 8 to 10 additional products over the next 3 years, with a strong focus on oncology and anti-infectives.</li>
<li><strong>CDMO Business:</strong> Seeing a growing number of inquiries and multiple RFQs being submitted. Now seen as a medium-term growth driver.</li>
<li><strong>Investment in Palvella Therapeutics Inc.:</strong> Strategic investment of $1 million in compulsory convertible notes to pave the way for a strategic partnership focused on the manufacturing and commercialization of QTORIN.</li>
<li><strong>Investment in CleanMax Private Limited:</strong> Acquiring a 26% equity stake in CleanMax to power Dholka plant with renewable energy.</li>
<li><strong>Injectable Plant:</strong> Scheduled to begin commercial production in the current quarter.</li>
<li><strong>Sustainability:</strong> Honored with the Sustainability Reporting Award from the Institute of Chartered Accountants of India.</li>
</ul>
<h2 class="heading" id="market--competitive-landscape">
  Market &amp; Competitive Landscape
  <a class="anchor" href="#market--competitive-landscape">#</a>
</h2>
<ul>
<li><strong>Formulation Business:</strong> Gaining strong acceptance among customers across various regions.</li>
<li><strong>Strategic Focus:</strong> Target domestic and emerging markets, leveraging expertise and market reach with an opportunistic approach for the regulated markets.</li>
<li><strong>Global Presence:</strong> Goal to establish a strong global presence and achieve market leadership, targeting a sizeable global market share within the next 5 years.</li>
</ul>
<h2 class="heading" id="risk-factors--challenges">
  Risk Factors &amp; Challenges
  <a class="anchor" href="#risk-factors--challenges">#</a>
</h2>
<ul>
<li><strong>Customer Procurement Patterns:</strong> &ldquo;Customer procurement patterns may lead to lumpiness, with some quarters experiencing higher procurement than others.&rdquo;</li>
<li><strong>Calendar Year Closure:</strong> Formulation segment revenues were impacted due to calendar year closure for many global clients.</li>
</ul>
<h2 class="heading" id="forward-looking-statements">
  Forward-Looking Statements
  <a class="anchor" href="#forward-looking-statements">#</a>
</h2>
<ul>
<li><strong>Growth Outlook:</strong> Positive outlook, in line with long-term guidance of achieving a 25% CAGR growth over the next 5 years.</li>
<li><strong>Formulation Business Growth:</strong> Anticipate substantial growth in both product offerings and customer acquisition in the Formulation business.</li>
<li><strong>CDMO Growth:</strong> CDMO is now seen as a medium-term growth driver.</li>
<li><strong>Injectable Plant Revenue:</strong> Revenue generation from the injectable plant is expected to build up over the next financial year.</li>
</ul>
<h2 class="heading" id="qa-insights">
  Q&amp;A Insights
  <a class="anchor" href="#qa-insights">#</a>
</h2>
<ul>
<li><strong>Revenue Growth:</strong> Analyst questioned if the current year growth guidance would be revised downward given the trailing 12-month revenues.</li>
<li><strong>CDMO:</strong> Analyst questioned the CDMO contracts.</li>
<li><strong>Capacity Utilization:</strong> Questions regarding the capacity utilization of all facilities.</li>
</ul>
<h2 class="heading" id="management-tone--sentiment">
  Management Tone &amp; Sentiment
  <a class="anchor" href="#management-tone--sentiment">#</a>
</h2>
<ul>
<li><strong>Stable Performance:</strong> Pleased to report stable performance for Q3 FY &lsquo;25.</li>
<li><strong>Positive Outlook:</strong> Outlook remains positive, in line with long-term guidance.</li>
<li><strong>Emphasis on Annual Assessment:</strong> &ldquo;I would still emphasize to assess our financial results on an annualized basis rather than a quarterly one.&rdquo;</li>
</ul>



<div class="button-container">    
    <a href="https://www.bseindia.com/xml-data/corpfiling/AttachHis/2331ef6f-b29f-45a9-8504-a240ea1b4f36.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/senco-gold-limited-q3-fy25-earnings-call2025-02-20/">
                        Senco Gold Limited: Q3 FY25 Earnings Call
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/integrated-industries-limited2025-02-22/">
                        Integrated Industries Limited: Q3 FY25 Earnings Call Transcript Analysis
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>